HLA*A2 confers mortality risk for cardiovascular disease in Pimans.
A sample of 1465 full heritage Piman Indians from Arizona were typed for the serological antigens of the HLA class I loci and then incorporated into a survival study that ended December 31, 1991. The total follow-up time was 11,749 person-years with an average of 8.0 years per person. During the study 298 persons died, 54 from cardiovascular disease (CVD). Allele HLA*A2 conferred a 4.94 fold rate for death from CVD (95% C.I. 1.91-12.77). When controlled for the potential confounding variables, cholesterol, mean blood pressure, smoking, body mass index, rheumatoid factor titer, and nephropathy, the mortality rate ratio (MRR) was 5.42 (95% C.I. 1.98-14.82). There was no statistically significant association of mortality with other HLA-A or HLA-B alleles, or for causes of death not related to cardiovascular disease.
Williams
R C
RC
Histocompatibility Laboratory, Blood Systems Inc., Scottsdale, Arizona, USA.
Hanson
R L
RL
Pettitt
D J
DJ
Sievers
M L
ML
Nelson
R G
RG
Knowler
W C
WC
D000328:Adult; D000368:Aged; D001130:Arizona / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality*; D005838:Genotype; D015234:HLA-A Antigens / Q000235:genetics; D015789:HLA-A2 Antigen / Q000235:genetics*; D015235:HLA-B Antigens / Q000235:genetics; D006801:Humans; D007198:Indians, North American / Q000235:genetics; D008875:Middle Aged; D012307:Risk Factors
D015234:HLA-A Antigens; D015789:HLA-A2 Antigen; D015235:HLA-B Antigens